When focusing on drugs where the ENI10 score was inversely correlated with the IC50 (Supplementary Table S4), this analysis identified bleomycin, a drug that induces an arrest in the G2-phase of the cell cycle (47), as well as Refametinib (MEK inhibitor), as potential potent treatments for breast tumors that display a high CD10 score (Fig. 2K; Supplementary Table S5). This evidence concerns the gene MAP2K7 and breast neoplasm.